Aurobindo Pharma Faces Profit Dip Amid Strong European Momentum

Aurobindo Pharma reported a 10% drop in its consolidated net profit to Rs 824 crore for the June quarter, primarily due to reduced sales in the US and its API business sectors. This contrasts with the Rs 918 crore net profit posted in the same period of the prior year.

Despite the profit decline, the company announced a revenue increase to Rs 7,868 crore, up from Rs 7,567 crore the previous year, according to a regulatory filing. K Nithyananda Reddy, Vice-Chairman and Managing Director, highlighted the strong growth of the European division and resilience of the core US business.

The board approved a 400% interim dividend, equating to Rs 4.00 per equity share, with August 8, 2025, set as the record date for payment. On Monday, company shares concluded 1.04% higher at Rs 1,090.90 on the BSE.

(With inputs from agencies.)